F8 and hemophilia: Regular prophylactic factor VIII replacement is currently the standard treatment for patients with severe haemophilia A (defined as FVIII levels < 1 IU/dL), and its introduction has greatly improved the prognosis, life expectancy, and quality of life (QoL) of subjects with haemophilia, particularly preventing spontaneous bleeding episodes into the joints or the muscles, and the developing of haemophilic arthropathy [2, 3].